Personalized immune T-cell therapy study for head and neck cancer
Part of Cancer clinical trials.
This study focuses on testing a personalized immune therapy (made from your tumor-fighting T cells) for people with head and neck cancer. It may help patients whose cancer is new and untreated or whose cancer has come back or is not responding to standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old (all genders).
- Your doctor expects you can live more than 3 months.
- You have head and neck cancer that is either newly diagnosed and not treated yet, or recurrent/advanced and not responding to effective treatment.
- A doctor can remove (harvest) your tumor tissue during surgery for study use.
- You’re willing to join and sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This study is looking for people with advanced head and neck cancer who have already received immunotherapy plus chemotherapy as their first treatment. Researchers will study your tumor tissue and proteins to find better ways to use immunotherapy.
This trial collects tissue and health information to find the best treatment for your head and neck cancer. It may help guide your care by looking at the genetic details of your tumor.
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
This study collects tissue from people with newly diagnosed head and neck squamous cell cancer and grows “mini tumor models” in the lab. The goal is to see how these models respond to new therapies, which may help guide more effective treatment choices in the future.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.